Status:
COMPLETED
Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)
Lead Sponsor:
University of Southern Denmark
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare changes in global left ventricular (LV) function after 3 months of treatment with irbesartan compared with usual care in patients with acute myocardial infarcti...
Detailed Description
Study objectives: Primary Objective: To compare the change in global LV function assessed with myocardial performance index (MPI) after 3 months treatment with irbesartan compared to usual care in p...
Eligibility Criteria
Inclusion
- Documented AMI; MPI \> 0.55
- Randomized within 7 days of AMI
- Written informed consent
Exclusion
- Age \< 18 years
- Any contraindications to angiotensin 2-receptor blockade
- In patients with WMSI \> 1.3 treatment with ACE-inhibitor or angiotensin 2-receptor blockers
- In patients with WMSI \<= 1.3 no initiated or planned treatment with an ACE-inhibitor. Treatment with an ACE-inhibitor must be started within 7 days
- Pregnancy or women of childbearing potential who are not using an effective method of contraception
- Other comorbid conditions that could influence the study
- Currently receiving an experimental study drug
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00125645
Start Date
March 1 2005
End Date
September 1 2011
Last Update
May 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kardiologisk Klinik, Centralsygehuset Esbjerg/Varde
Esbjerg, Denmark, 6700